CRBN Stock Analysis: Corbion | AS

Specialty Chemicals | AS, Netherlands | Market Cap: 1.531m EUR | 12M Return: 45.2% | NL0010583399 | Charts, Fundamentals & Technical Analysis

Lactic Acid, Algae Nutritionals, Preservatives, Biopolymers
Total Rating 61
Safety 88
Buy Signal 1.15
Specialty Chemicals
Sub-Industry Rotation: -3.6
Market Cap: 1.68B
Avg Turnover: 3.76M
Risk 3d forecast
Volatility29.4%
VaR 5th Pctl4.21%
VaR vs Median-9.43%
Reward TTM
Sharpe Ratio1.44
Rel. Str. IBD93.6
Rel. Str. Peer Group96.3 pctl
Character TTM
Beta0.419
Beta Downside0.401
Hurst Exponent0.579
Choppyness18.7%
Drawdowns 3y
Max DD35.05%
CAGR/Max DD0.56
CAGR/Mean DD1.23

Warnings

No concerns identified

Tailwinds

Supp Ema20
Rs Leader
Idiosyncratic Leader
Calm

Seasonality 11.9 years of data, until 10/2026

Jan +0.8% 0
Feb -2.2% 4
Mar -1.4% 4
Apr +6.1% 28
May -0.4% 4
Jun -2.9% 14
Jul -0.2% 4
Aug +1.6% 4
Sep -0.6% 0
Oct -1.2% 4
Nov +5.2% 9
Dec +0.9% 9

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: CRBN Corbion

Corbion N.V. is a Dutch specialty chemicals company founded in 1903 and headquartered in Amsterdam. It produces lactic acid and derivatives, food preservation solutions, functional ingredient systems, and algae-based nutritional ingredients, serving markets across Europe, the Americas, Asia, the Middle East, and Africa. The company operates through two business segments: Functional Ingredients & Solutions, and Health & Nutrition. Its extensive product portfolio spans additives and ingredients for food, feed, personal care, pharmaceuticals, and industrial applications, with a long list of branded offerings such as PURAC, PURASOLV, PURASORB, and AlgaPrime DHA. The company was previously known as CSM N.V. before rebranding to Corbion N.V. in October 2013.

As a specialty chemicals producer, Corbion operates in a sector that supplies value-added chemical inputs to a wide range of downstream industries, including food and beverage manufacturing, animal nutrition, personal care, and pharmaceuticals. Its focus on lactic acid and algae-derived ingredients places it at the intersection of the bio-based and sustainable ingredients trend, where companies develop renewable, fermentation-based alternatives to traditional petrochemical-derived products.

Headlines to Watch Out For
  • Algae-based omega-3 demand grows as aquaculture feed market expands
  • PLA bioplastics revenue scales on sustainable packaging regulation
  • Health & Nutrition margins pressured by lactic acid feedstock costs
Piotroski VR-10 (Strict) 4.0
Net Income: 62.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA -1.79 > 1.0
NWC/Revenue: 23.06% < 20% (prev 7.01%; Δ 16.05% < -1%)
CFO/TA 0.10 > 3% & CFO 144.2m > Net Income 62.2m
Net Debt (533.3m) to EBITDA (186.4m): 2.86 < 3
Current Ratio: 1.83 > 1.5 & < 3
Outstanding Shares: last quarter (58.4m) vs 12m ago -0.50% < -2%
Gross Margin: 25.05% > 18% (prev 26.10%; Δ -1.05% > 0.5%)
Asset Turnover: 85.16% > 50% (prev 89.21%; Δ -4.05% > 0%)
Interest Coverage Ratio: 5.39 > 6 (EBIT TTM 100.2m / Interest Expense TTM 18.6m)
Altman Z'' 4.31
A: 0.19 (Total Current Assets 635.1m - Total Current Liabilities 346.2m) / Total Assets 1.49b
B: 0.46 (Retained Earnings 681.8m / Total Assets 1.49b)
C: 0.07 (EBIT TTM 100.2m / Avg Total Assets 1.47b)
D: 1.03 (Book Value of Equity 755.7m / Total Liabilities 733.3m)
Altman-Z'' = 4.31 = AA
Beneish M -3.01
DSRI: 1.36 (Receivables 274.6m/208.4m, Revenue 1.25b/1.30b)
GMI: 1.04 (GM 26.10% / 25.05%)
AQI: 0.52 (AQ_t 0.08 / AQ_t-1 0.16)
SGI: 0.97 (Revenue 1.25b / 1.30b)
TATA: -0.06 (NI 62.2m - CFO 144.2m) / TA 1.49b)
Beneish M = -3.01 (Cap -4..+1) = AA
What is the price of CRBN shares?

As of November 19, 2026, the stock is trading at EUR 25.90 with a total of 86,373 shares traded. Over the past week, the price has changed by -2.63%, over one month by +10.21%, over three months by +30.09% and over the past year by +45.21%.

Current recommended Stop Loss: 25.10 (which is 3.1% or 1.2 ATR below the current price).

Is CRBN a buy, sell or hold?

Corbion has no consensus analysts rating.

Corbion (CRBN) - Fundamental Data Overview as of 16 November 2026
Market Cap USD = 1.68b (1.53b EUR * 1.09717 EUR.USD)
P/E Trailing = 25.0566
P/E Forward = 15.1745
P/S = 1.2222
P/B = 2.0262
P/EG = 1.2623
Revenue TTM = 1.25b EUR
EBIT TTM = 100.2m EUR
EBITDA TTM = 186.4m EUR
Long Term Debt = 320.2m EUR (from longTermDebt, last quarter)
Short Term Debt = 156.3m EUR (from shortTermDebt, last quarter)
Debt = 569.3m EUR (from shortLongTermDebtTotal, last quarter) + Leases 51.7m
Net Debt = 533.3m EUR (calculated: Debt 569.3m - CCE 36.0m)
Enterprise Value = 2.06b EUR (1.53b + Debt 569.3m - CCE 36.0m)
Interest Coverage Ratio = 5.39 (Ebit TTM 100.2m / Interest Expense TTM 18.6m)
EV/FCF = 27.31x (Enterprise Value 2.06b / FCF TTM 75.6m)
FCF Yield = 3.66% (FCF TTM 75.6m / Enterprise Value 2.06b)
FCF Margin = 6.03% (FCF TTM 75.6m / Revenue TTM 1.25b)
Net Margin = 4.96% (Net Income TTM 62.2m / Revenue TTM 1.25b)
Gross Margin = 25.05% ((Revenue TTM 1.25b - Cost of Revenue TTM 939.0m) / Revenue TTM)
Gross Margin QoQ = 24.47% (prev 25.65%)
Tobins Q-Ratio = 1.39 (Enterprise Value 2.06b / Total Assets 1.49b)
Interest Expense / Debt = 3.27% (Interest Expense 18.6m / Debt 569.3m)
Taxrate = 22.54% (18.1m / 80.3m)
NOPAT = 77.6m (EBIT 100.2m * (1 - 22.54%))
Current Ratio = 1.83 (Total Current Assets 635.1m / Total Current Liabilities 346.2m)
Debt / Equity = 0.75 (Debt 569.3m / totalStockholderEquity, last quarter 755.7m)
Debt / EBITDA = 2.86 (Net Debt 533.3m / EBITDA 186.4m)
Debt / FCF = 7.05 (Net Debt 533.3m / FCF TTM 75.6m)
Total Stockholder Equity = 749.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.23% (Net Income 62.2m / Total Assets 1.49b)
RoE = 8.30% (Net Income TTM 62.2m / Total Stockholder Equity 749.2m)
RoCE = 9.37% (EBIT 100.2m / Capital Employed (Equity 749.2m + L.T.Debt 320.2m))
RoIC = 6.14% (NOPAT 77.6m / Invested Capital 1.26b)
WACC = 5.83% (E(1.53b)/V(2.10b) * Re(7.05%) + D(569.3m)/V(2.10b) * Rd(3.27%) * (1-Tc(0.23)))
Discount Rate = 7.05% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -86.47 | Cagr: -1.62%
[DCF] Terminal Value 73.10% ; FCFF base≈85.3m ; Y1≈74.8m ; Y5≈60.4m
[DCF] Fair Price = 7.57 (EV 969.9m - Net Debt 533.3m = Equity 436.6m / Shares 57.7m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: -90.15 | Revenue CAGR: -4.88% | SUE: 0.90 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=1.38 | Chg30d=+4.56% | Revisions=+38% | GrowthEPS=+4.4% | GrowthRev=+3.2%
EPS next Year (2027-12-31): EPS=1.73 | Chg30d=+11.72% | Revisions=+62% | GrowthEPS=+25.8% | GrowthRev=+4.7%
[Analyst] Revisions Ratio: +62% (up=9, down=1)